Risperidone induced tardive movements in an elderly male-a case of cognitive decline masked by behavioral abnormalities
https://doi.org/10.4081/gc.2022.10818
Accepted: 23 December 2022
HTML: 35
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Tardive dyskinesia is a drug emergent side effect associated with long-term exposure to neuroleptics. Risperidone has lesser propensity to cause tardive movements. A 67-year-old male presented with tardive symptoms. He had oromasticatory and limb movements. He was started on 2 mg of risperidone for agitation and behavioral disturbance 4 years ago. He also developed cognitive decline over the years. Clinician must be aware of the possibility of tardive movements with risperidone and the need for frequent evaluation of cognitive function in any elderly male.
Henderson M, Millers JDC. Movements disorders in organic psychiatry a textbook of neuropsychiatry. Fourth Edition. West Sussex: Wiley-Blackwell Publishers; 2009. pp.747-8.
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiat 2008:21:151-6. DOI: https://doi.org/10.1097/YCO.0b013e3282f53132
Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiat 2000:61:27-32.
Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat 2019;15:785-94. DOI: https://doi.org/10.2147/NDT.S196541
Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiat 2000;157:1150-5. DOI: https://doi.org/10.1176/appi.ajp.157.7.1150
Goldberg RJ. Tardive dyskinesia in elderly patients: an update. J Am Med Dir Assoc 2003;4:S33-42. DOI: https://doi.org/10.1016/S1525-8610(04)70303-5
Aquino CCH, Lang AE. Parkinsonism. Relat Disord 2014;S113-7. DOI: https://doi.org/10.1016/S1353-8020(13)70028-2
Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat 2013;9:1371-80. DOI: https://doi.org/10.2147/NDT.S30767
Thaker GK, Nguyen JA, et al. Clonazepam treatment of tardive dyskinesia: a practical GABA mimetic strategy. Am J Psychiatry 1990;147:445-51. DOI: https://doi.org/10.1176/ajp.147.4.445
Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiat 2003;64:1342-8. DOI: https://doi.org/10.4088/JCP.v64n1110
Kumar S, Malone DM. Risperidone implicated in the onset of tardive dyskinesia in a young woman. Postgrad Med J 2000;76:316-7. DOI: https://doi.org/10.1136/pmj.76.895.316
Tandon R. Risperidone improves severe tardive dyskinesia in people with schizophrenia. Evid Based Ment Health 2004;7:83. DOI: https://doi.org/10.1136/ebmh.7.3.83
Ismail Z, Creese B, Aarsland D, et al. Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities. Nat Rev Neurol 2022;18:131-44. DOI: https://doi.org/10.1038/s41582-021-00597-3
Cummings J, Pinto L, Cruz M, et al. Criteria for psychosis in major and mild neurocognitive disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. Am J Geriatr Psychiatry 2020;28:1256-69. DOI: https://doi.org/10.1016/j.jagp.2020.09.002
Meiner Z, Ayers E, Verghese J. Motoric cognitive risk syndrome: a risk factor for cognitive impairment and dementia in different populations. Ann Geriatr Med Res 2020;24:3-14. DOI: https://doi.org/10.4235/agmr.20.0001
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
